Liquidia Corp (LQDA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$222.8M
Cash & Equivalents
$53.0M
Quarterly Burn Rate
$6,930M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06129240 | An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH | OTHER | Recruiting | 80 |
| NCT04691154 | A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD | PHASE3 | Active Not Recruiting | 28 |
| NCT03992755 | Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprosti... | PHASE3 | Active Not Recruiting | 92 |
| NCT07285655 | A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD | PHASE3 | Recruiting | 344 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.